- Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
- Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
- Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
- Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
- Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
As of last trade Pacira Biosciences Inc (82P:MUN) traded at 18.50, 3.35% above its 52-week low of 17.90, set on Jul 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.50 |
---|---|
High | 18.50 |
Low | 18.50 |
Bid | 18.50 |
Offer | 18.70 |
Previous close | 17.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 46.55m |
Free float | 45.81m |
P/E (TTM) | 16.20 |
Market cap | 977.00m USD |
EPS (TTM) | 1.30 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 07:04 BST.
More ▼